Company: APM
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001213900-25-037669
Chunk: 168

Company: Aptorum Group Ltd
Filing Date: 2025-04-30
Form: 20-F
Item: Item 5
Chunk 168
---
Item 5. OPERATING AND FINANCIAL REVIEW AND
PROSPECTS

The following discussion of
our financial condition and results of operations is based upon and should be read in conjunction with our consolidated financial statements
and their related notes included in this annual report.

For purposes of Item 5, reference
to the “ We”, “ Our”, “ Ours” or “ Group” means Aptorum Group Limited and all of its subsidiaries.

This annual report includes consolidated financial statements for the
years ended December 31, 2024, 2023, and 2022. However, as permitted by Instruction 6 to Item 5 of Form 20-F, a discussion of the changes
in our results of operations for the years ended December 31, 2022, and 2021 has been omitted from this annual report, but may be found
in “ Item 5. Operating And Financial Review And Prospects” in our annual report on Form 20-F for the year ended
December 31, 2022, filed with the SEC on April 28, 2023.

This annual report contains
forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to
us. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance
or achievements to be materially different from those expressed or implied by the forward-looking statements.

You can identify these forward-looking
statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,”
“estimate,” “intend,” “plan,” “believe,” “potential,” “continue,”
“is/are likely to” or other similar expressions. We have based these forward-looking statements largely on our current expectations
and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business
strategy and financial needs. These forward-looking statements include, among other things, statements relating to:

  our goals and strategies;  

  our future business development, financial conditions and results of operations;  

  our expectations regarding demand for and market acceptance of our products once available;  

  our expectations regarding our development and commercialization of our therapeutics;  

  competition in our industry; and  

  relevant government policies and regulations relating to our industry.  

You should thoroughly read
this annual report and the documents that we refer to in this annual report with the understanding that our actual results in the